🇺🇸 FDA
Pipeline program

EYU688

CEYU688A12201

Phase 2 small_molecule active

Quick answer

EYU688 for Dengue is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Dengue
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials